Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination with Standard of Care Treatment in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Principal Investigator: Hillengass, Jens

AFT-65/ASCENT-05 OptimICE-RD: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After…

Principal Investigator: Levine, Ellis G

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined with IFN alpha2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients with Metastatic Triple Negative Breast Cancer

Principal Investigator: Gandhi, Shipra

Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition

Principal Investigator: Chatta, Gurkamal S

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -based Treatment in
Combination with Tumor-Selective Chemokine Modulation (CKM: Interferon alpha-2b,
Rintatolimod and Celecoxib) in Melanoma Patients with Primary PD-1/PD-L1 Resistance

Principal Investigator: Puzanov, Igor

(ID-COMET) A Randomized Phase III Trial of Immediate Versus Six-Month Delayed Comprehensive Treatment of 1-10 Oligometastatic Tumors With or Without Synchronous Primary

Principal Investigator: Singh, Anurag K

Feasibility of a Community-Based Cancer Survivor Exercise and Nutrition Education Program: Effects on Self Efficacy, Quality of Life and Functional Performance

Principal Investigator: Ray, Andrew D

A Phase 1, Open-Label, Dose Escalation and Expansion Study of ASP1012, an Oncolytic Virus, in Participants with Locally Advanced or Metastatic Solid Tumors ( 1012-CL-0101)

Principal Investigator: Switzer, Benjamin J

A Phase II Study of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

Principal Investigator: Green, Steven D

(AHOD2131) A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Principal Investigator: Kelly, Kara M

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers

Principal Investigator: Gandhi, Shipra

(ACCL2433) Risk-Based 6MP Adherence Enhancement Strategies in Children, Adolescent and Young Adults with ALL - A Pilot Study

Principal Investigator: Twist, Clare J

A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer ( 27T51-01)

Principal Investigator: Zsiros, Emese

Feasibility Study for ivWatch in prevention of extravasation of vesicants in an oncology setting

Principal Investigator: Storer, Andrew C

Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)

Principal Investigator: Prasad, Dheerendra

A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors

Principal Investigator: Dy, Grace K

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate…

Principal Investigator: Green, Steven D

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation

Principal Investigator: Wang, Eunice S

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)

Principal Investigator: Malek, Ehsan

Investigating The Effect of Testosterone Replacement Therapy Among Hypogonadal Men with Localized Prostate Cancer on Active Surveillance

Principal Investigator: Aly, Ahmed A

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 in Patients with Recurrent Ovarian Cancer

Principal Investigator: Zsiros, Emese

2215-CL-0203 A Phase 1/2, Multicenter, Open-Label, Randomized, Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for…

Principal Investigator: Wang, Eunice S

(EA7222) A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Principal Investigator: Gupta, Ajay

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Principal Investigator: McLean, Karen

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Principal Investigator: George, Saby